These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34952480)

  • 1. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
    Goldinger SM; Buder-Bakhaya K; Lo SN; Forschner A; McKean M; Zimmer L; Khoo C; Dummer R; Eroglu Z; Buchbinder EI; Ascierto PA; Gutzmer R; Rozeman EA; Hoeller C; Johnson DB; Gesierich A; Kölblinger P; Bennannoune N; Cohen JV; Kähler KC; Wilson MA; Cebon J; Atkinson V; Smith JL; Michielin O; Long GV; Hassel JC; Weide B; Haydu LE; Schadendorf D; McArthur G; Ott PA; Blank C; Robert C; Sullivan R; Hauschild A; Carlino MS; Garbe C; Davies MA; Menzies AM
    Eur J Cancer; 2022 Feb; 162():22-33. PubMed ID: 34952480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
    Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
    Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
    Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.
    Cabezas-Camarero S; Cabrera-Martín MN; Merino-Menéndez S; Paz-Cabezas M; García-Barberán V; Sáiz-Pardo Sanz M; Iglesias-Moreno M; Alonso-Ovies A; Pérez-Segura P
    Oncologist; 2021 Jun; 26(6):e1018-e1035. PubMed ID: 33751752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?
    Klee G; Hagelstein V; Kurzhals JK; Zillikens D; Terheyden P; Langan EA
    Melanoma Res; 2022 Oct; 32(5):360-365. PubMed ID: 35855658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
    Meynard L; Dinart D; Delaunay B; Fléchon A; Saldana C; Lefort F; Gravis G; Thiery-Vuillemin A; Cancel M; Coquan E; Ladoire S; Maillet D; Rolland F; Boughalem E; Martin S; Laramas M; Crouzet L; Abbar B; Falkowski S; Pouessel D; Roubaud G
    Eur J Cancer; 2022 Nov; 175():43-53. PubMed ID: 36088671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.
    Lee CK; Jung M; Choi HJ; Kim HR; Kim HS; Roh MR; Ahn JB; Chung HC; Heo SJ; Rha SY; Shin SJ
    Cancer Res Treat; 2015 Oct; 47(4):781-9. PubMed ID: 25687848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review.
    Li J; Kan H; Zhao L; Sun Z; Bai C
    Ther Adv Med Oncol; 2020; 12():1758835920922028. PubMed ID: 32489431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
    van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
    Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.
    Di Pietro FR; Marinelli D; Verkhovskaia S; Poti G; Falcone R; Carbone ML; Morelli MF; Zappalà AR; Di Rocco ZC; Morese R; Piesco G; Chesi P; Marchetti P; Failla CM; De Galitiis F
    BMC Cancer; 2024 Oct; 24(1):1220. PubMed ID: 39354418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
    Bouchereau S; Chaplain L; Fort M; Beauchet A; Sidibé T; Chapalain M; Gonzalez-Lara L; Longvert C; Blom A; Saiag P; Funck-Brentano E
    Br J Cancer; 2021 Sep; 125(7):948-954. PubMed ID: 34262147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
    Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
    Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
    Vera Aguilera J; Paludo J; McWilliams RR; Zhang H; Li Y; Kumar AB; Failing J; Kottschade LA; Block MS; Markovic SN; Dong H; Dronca RS; Yan Y
    Melanoma Res; 2020 Aug; 30(4):364-375. PubMed ID: 32404734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
    Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.
    Klemen ND; Wang M; Feingold PL; Cooper K; Pavri SN; Han D; Detterbeck FC; Boffa DJ; Khan SA; Olino K; Clune J; Ariyan S; Salem RR; Weiss SA; Kluger HM; Sznol M; Cha C
    J Immunother Cancer; 2019 Jul; 7(1):196. PubMed ID: 31340861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma.
    Li JJ; Wang JH; Dingv Y; Li DD; Wen XZ; Zhao JJ; Jiang H; Liu X; Huang FX; Zhang XS
    J Cancer Res Clin Oncol; 2022 May; 148(5):1159-1169. PubMed ID: 34181096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of immune checkpoint inhibitors for in-transit melanoma.
    Nan Tie E; Lai-Kwon J; Rtshiladze MA; Na L; Bozzi J; Read T; Atkinson V; Au-Yeung G; Long GV; McArthur GA; Sandhu S; Saw R; Walpole E; Menzies A; Smithers M; Gyorki DE
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.